Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial

BACKGROUND: Abrocitinib, an oral Janus kinase 1 inhibitor, provided significant itch relief by week 2 in patients with moderate-to-severe atopic dermatitis (AD) in the phase III JADE COMPARE trial. OBJECTIVES: This post-hoc analysis of JADE COMPARE aimed to further characterize itch response and det...

Descripción completa

Detalles Bibliográficos
Autores principales: Ständer, Sonja, Kwatra, Shawn G., Silverberg, Jonathan I., Simpson, Eric L., Thyssen, Jacob P., Yosipovitch, Gil, Zhang, Fan, Cameron, Michael C., Cella, Ricardo Rojo, Valdez, Hernan, DiBonaventura, Marco, Feeney, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032219/
https://www.ncbi.nlm.nih.gov/pubmed/36512175
http://dx.doi.org/10.1007/s40257-022-00738-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032219/
https://www.ncbi.nlm.nih.gov/pubmed/36512175
http://dx.doi.org/10.1007/s40257-022-00738-4

Ejemplares similares